{"transactions":[{"id":1834678,"issuer":{"id":111578,"kind":"organization","name":"REGENERX BIOPHARMACEUTICALS INC","symbol":"RGRX"},"owners":[{"id":111579,"kind":"person","name":"Essetifin SPA","position":1,"cik":"0001092601","reported_name":"Essetifin SPA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111580,"kind":"person","name":"CAVAZZA PAOLO","position":2,"cik":"0001163608","reported_name":"CAVAZZA PAOLO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111581,"kind":"person","name":"Cavazza Enrico","position":3,"cik":"0001525744","reported_name":"Cavazza Enrico","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111582,"kind":"person","name":"Cavazza Francesca","position":4,"cik":"0001525742","reported_name":"Cavazza Francesca","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111583,"kind":"person","name":"Cavazza Silvia","position":5,"cik":"0001525743","reported_name":"Cavazza Silvia","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111584,"kind":"person","name":"Cavazza Preta Martina","position":6,"cik":"0001718557","reported_name":"Cavazza Preta Martina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111585,"kind":"person","name":"APTAFIN S P A","position":7,"cik":"0001232942","reported_name":"APTAFIN S P A","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock Warrant (right to buy)","published_at":"2023-07-06T16:30:14.000Z","date":"2023-07-03","kind":"other","planned":false,"acquired":true,"shares":3750000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the \"2023 Agreement\"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the \"2023 Note\") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the \"2023 Warrant\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The 2023 Warrant is exercisable into up to 3,750,000 shares of the issuer's common stock and is exercisable, in whole or in part, at any time and from time to time, from January 3, 2024, the date that is six months after the date of purchase, through July 2, 2028, the fifth anniversary of such date."},{"field":"shares","element":"transactionShares","label":"F7","text":"On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the \"2023 Agreement\"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the \"2023 Note\") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the \"2023 Warrant\")."},{"field":"shares","element":"transactionShares","label":"F9","text":"The 2023 Warrant is exercisable into up to 3,750,000 shares of the issuer's common stock and is exercisable, in whole or in part, at any time and from time to time, from January 3, 2024, the date that is six months after the date of purchase, through July 2, 2028, the fifth anniversary of such date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the \"2023 Agreement\"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the \"2023 Note\") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the \"2023 Warrant\")."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The 2023 Warrant is exercisable into up to 3,750,000 shares of the issuer's common stock and is exercisable, in whole or in part, at any time and from time to time, from January 3, 2024, the date that is six months after the date of purchase, through July 2, 2028, the fifth anniversary of such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the \"2023 Agreement\"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the \"2023 Note\") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the \"2023 Warrant\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F9","text":"The 2023 Warrant is exercisable into up to 3,750,000 shares of the issuer's common stock and is exercisable, in whole or in part, at any time and from time to time, from January 3, 2024, the date that is six months after the date of purchase, through July 2, 2028, the fifth anniversary of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the \"2023 Agreement\"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the \"2023 Note\") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the \"2023 Warrant\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"The 2023 Warrant is exercisable into up to 3,750,000 shares of the issuer's common stock and is exercisable, in whole or in part, at any time and from time to time, from January 3, 2024, the date that is six months after the date of purchase, through July 2, 2028, the fifth anniversary of such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F11","text":"Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza may be deemed to indirectly beneficially own the securities of the issuer purchased by Essetifin. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all securities of the issuer held by Essetifin except to the extent of any pecuniary interest therein."}],"balance_after":3750000,"derivative":{"exercise_price":0.02,"exercise_date":"2024-01-03","expiration_date":"2028-07-02","underlying":"Common Stock","underlying_shares":3750000},"source":{"system":"sec-edgar","filing":"0001213900-23-055186","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/707511/000121390023055186/ownership.xml","form_type":"4"}},{"id":1834677,"issuer":{"id":111578,"kind":"organization","name":"REGENERX BIOPHARMACEUTICALS INC","symbol":"RGRX"},"owners":[{"id":111579,"kind":"person","name":"Essetifin SPA","position":1,"cik":"0001092601","reported_name":"Essetifin SPA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111580,"kind":"person","name":"CAVAZZA PAOLO","position":2,"cik":"0001163608","reported_name":"CAVAZZA PAOLO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111581,"kind":"person","name":"Cavazza Enrico","position":3,"cik":"0001525744","reported_name":"Cavazza Enrico","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111582,"kind":"person","name":"Cavazza Francesca","position":4,"cik":"0001525742","reported_name":"Cavazza Francesca","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111583,"kind":"person","name":"Cavazza Silvia","position":5,"cik":"0001525743","reported_name":"Cavazza Silvia","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111584,"kind":"person","name":"Cavazza Preta Martina","position":6,"cik":"0001718557","reported_name":"Cavazza Preta Martina","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111585,"kind":"person","name":"APTAFIN S P A","position":7,"cik":"0001232942","reported_name":"APTAFIN S P A","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Convertible Promissory Note (right to buy)","published_at":"2023-07-06T16:30:14.000Z","date":"2023-07-03","kind":"purchase","planned":false,"acquired":true,"price":50000,"reported_value":50000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the \"2023 Agreement\"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the \"2023 Note\") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the \"2023 Warrant\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The 2023 Note and any accrued interest thereon are convertible at the option of the holder at any time commencing six months after the date of issuance and prior to repayment of the 2023 Note into shares of the issuer's common stock at a conversion price of $0.02 per share. The 2023 Note is payable upon the written demand of the holder thereof at any time after July 2, 2028. Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the maturity date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within two business days after conversion."},{"field":"reported_value","element":"transactionTotalValue","label":"F7","text":"On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the \"2023 Agreement\"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the \"2023 Note\") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the \"2023 Warrant\")."},{"field":"reported_value","element":"transactionTotalValue","label":"F8","text":"The 2023 Note and any accrued interest thereon are convertible at the option of the holder at any time commencing six months after the date of issuance and prior to repayment of the 2023 Note into shares of the issuer's common stock at a conversion price of $0.02 per share. The 2023 Note is payable upon the written demand of the holder thereof at any time after July 2, 2028. Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the maturity date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within two business days after conversion."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the \"2023 Agreement\"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the \"2023 Note\") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the \"2023 Warrant\")."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The 2023 Note and any accrued interest thereon are convertible at the option of the holder at any time commencing six months after the date of issuance and prior to repayment of the 2023 Note into shares of the issuer's common stock at a conversion price of $0.02 per share. The 2023 Note is payable upon the written demand of the holder thereof at any time after July 2, 2028. Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the maturity date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within two business days after conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the \"2023 Agreement\"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the \"2023 Note\") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the \"2023 Warrant\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The 2023 Note and any accrued interest thereon are convertible at the option of the holder at any time commencing six months after the date of issuance and prior to repayment of the 2023 Note into shares of the issuer's common stock at a conversion price of $0.02 per share. The 2023 Note is payable upon the written demand of the holder thereof at any time after July 2, 2028. Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the maturity date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within two business days after conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the \"2023 Agreement\"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the \"2023 Note\") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the \"2023 Warrant\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F8","text":"The 2023 Note and any accrued interest thereon are convertible at the option of the holder at any time commencing six months after the date of issuance and prior to repayment of the 2023 Note into shares of the issuer's common stock at a conversion price of $0.02 per share. The 2023 Note is payable upon the written demand of the holder thereof at any time after July 2, 2028. Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the maturity date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within two business days after conversion."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F7","text":"On July 3, 2023, in a private placement by the issuer, Essetifin entered into a Convertible Note and Warrant Purchase Agreement (the \"2023 Agreement\"), pursuant to which it agreed to purchase, for an aggregate purchase price of $50,000, (i) a convertible promissory note in the principal amount of $50,000 (the \"2023 Note\") and (ii) a warrant to purchase up to 3,750,000 shares of common stock at an exercise price of $0.02 per share, issued in connection with the 2023 Agreement as partial consideration for the 2023 Note (the \"2023 Warrant\")."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F8","text":"The 2023 Note and any accrued interest thereon are convertible at the option of the holder at any time commencing six months after the date of issuance and prior to repayment of the 2023 Note into shares of the issuer's common stock at a conversion price of $0.02 per share. The 2023 Note is payable upon the written demand of the holder thereof at any time after July 2, 2028. Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the maturity date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within two business days after conversion."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F11","text":"Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza may be deemed to indirectly beneficially own the securities of the issuer purchased by Essetifin. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all securities of the issuer held by Essetifin except to the extent of any pecuniary interest therein."}],"derivative":{"exercise_date":"2024-01-03","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-23-055186","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/707511/000121390023055186/ownership.xml","form_type":"4"}}]}